| __timestamp | Genmab A/S | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 31073000 |
| Thursday, January 1, 2015 | 91224000 | 43216000 |
| Friday, January 1, 2016 | 102413000 | 50679000 |
| Sunday, January 1, 2017 | 146987000 | 79171000 |
| Monday, January 1, 2018 | 213695000 | 168218000 |
| Tuesday, January 1, 2019 | 342000000 | 210796000 |
| Wednesday, January 1, 2020 | 661000000 | 203613000 |
| Friday, January 1, 2021 | 1283000000 | 234273000 |
| Saturday, January 1, 2022 | 2676000000 | 265784000 |
| Sunday, January 1, 2023 | 3297000000 | 344501000 |
| Monday, January 1, 2024 | 3790000000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Genmab A/S and Insmed Incorporated, from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects Genmab's aggressive expansion and investment in operational capabilities. In contrast, Insmed Incorporated's SG&A expenses have grown at a steadier pace, increasing by around 1,000% over the same period, reaching $345 million in 2023. This comparison highlights Genmab's rapid growth strategy, while Insmed maintains a more measured approach. Understanding these trends provides valuable insights into each company's strategic priorities and market positioning.
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.